VVUS: VIVUS INC. (NASDAQ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: VLAD who wrote (8667)	5/29/1998 8:38:00 AM
From: DaiS	of 23519

Vlad, During my coffee break I followed your altercation with Dale Russel re the AUA meeting abstracts. I agree that he is biased against muse. In the VA study, apart from the points you make, 84% were frightened of needles, and 25 out of the 107 did not respond to injections, hardly good candidates for muse!! In the muse vs caverject study there were no differences when the higher muse dose was used. And at the lower dose the difference 8:14 in the numbers opting for muse:caverject is not statistically significant. In the study in the urology practice setting the dropout from 27% to 18%, the "Most disappointing..." conclusion is nowhere near significant given N=115. N>300 would be required. This latter study seems the most powerful negative one at the meeting and I don't agree that the scales are on the negative side for muse overall. The Nexmed and MCHM abstracts are a joke - to think nexmed went up 80% in one day DaiS

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next